Meeting report. Report from ICAAC.
Sax
Paul E
PE
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate; D048588:Benzoxazines; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use; D003521:Cyclopropanes; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use; D009930:Organic Chemicals / Q000627:therapeutic use; D010755:Organophosphates / Q000008:administration & dosage / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use; D010349:Patient Compliance; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D005663:Furans; D009842:Oligopeptides; D009930:Organic Chemicals; D010755:Organophosphates; D010078:Oxazines; D011725:Pyridines; D011760:Pyrrolidinones; D013449:Sulfonamides; D000068898:Raltegravir Potassium; D000069446:Atazanavir Sulfate; C098320:efavirenz; D019438:Ritonavir; C426859:fosamprenavir